114 related articles for article (PubMed ID: 19322010)
1. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Curigliano G; Spitaleri G; De Cobelli O; Scardino E; Sbanotto A; de Braud F
Urol Int; 2009; 82(2):196-202. PubMed ID: 19322010
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Curigliano G; De Braud F; Teresa Sandri M; Renne G; Zorzino L; Scardino E; Rocco B; Spitaleri G; De Pas T; Noberasco C; Nolè F; Verweij F; Matei V; De Cobelli O
Anticancer Drugs; 2007 Sep; 18(8):949-54. PubMed ID: 17667601
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
[TBL] [Abstract][Full Text] [Related]
4. Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.
Beer TM; Eilers KM; Garzotto M; Hsieh YC; Mori M
Cancer; 2004 Feb; 100(4):758-63. PubMed ID: 14770432
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life among patients with metastatic prostate cancer.
Albertsen PC; Aaronson NK; Muller MJ; Keller SD; Ware JE
Urology; 1997 Feb; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
[TBL] [Abstract][Full Text] [Related]
6. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
; Berry DL; Moinpour CM; Jiang CS; Ankerst DP; Petrylak DP; Vinson LV; Lara PN; Jones S; Taplin ME; Burch PA; Hussain MH; Crawford ED
J Clin Oncol; 2006 Jun; 24(18):2828-35. PubMed ID: 16782921
[TBL] [Abstract][Full Text] [Related]
7. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Curigliano G; Pelosi G; De Pas T; Renne G; De Cobelli O; Manzotti M; Spitaleri G; de Braud F
Prostate; 2007 May; 67(6):603-4. PubMed ID: 17290443
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
9. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
Tannock IF; Osoba D; Stockler MR; Ernst DS; Neville AJ; Moore MJ; Armitage GR; Wilson JJ; Venner PM; Coppin CM; Murphy KC
J Clin Oncol; 1996 Jun; 14(6):1756-64. PubMed ID: 8656243
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
13. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Wilding G; Soulie P; Trump D; Das-Gupta A; Small E
Cancer; 2006 May; 106(9):1917-24. PubMed ID: 16568471
[TBL] [Abstract][Full Text] [Related]
14. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Inamoto T; Takahara K; Nishimura Y; Segawa N; Katsuoka Y
Am J Clin Oncol; 2008 Apr; 31(2):188-94. PubMed ID: 18391605
[TBL] [Abstract][Full Text] [Related]
15. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E
BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854
[TBL] [Abstract][Full Text] [Related]
16. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
17. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
18. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
19. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
